Xortx announces $2 million public offering

Not for distribution to united states news wire servicesor for dissemination in the united states calgary, alberta, jan. 15, 2024 (globe newswire) -- xortx therapeutics inc. (“xortx” or the “company”) (nasdaq: xrtx | tsxv: xrtx | frankfurt: anu), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces the filing of a prospectus supplement on a non-brokered offering of up to 666,667 common share units (“common share units”), with each common share unit consisting of one common share, no par value, and one warrant (“warrant”) to purchase one common share at $4.50 per common share for a period of two years for aggregate gross proceeds of up to $2 million, prior to deducting offering expenses (the “offering”). the common shares and warrants contained in the common share units are immediately separable upon issuance.
XRTX Ratings Summary
XRTX Quant Ranking